Etienne Jacotot (EJ; PhD, DR2 Inserm, Visiting Prof. Imperial College London) is an expert of programmed cell death and translational applications. He carried out his main post-doctoral research training with Professor Guido Kroemer at Institut Gustave Roussy (Villejuif, France), where he worked on the mitochondrial control of apoptosis and contributed to the characterization of apoptosis-inducing factor (AIF). Exploring the apoptogenic effects of viral proteins he provided the 1st example of viral pro-apoptotic protein (HIV-1 Vpr) able to interact directly with mitochondrial membranes to trigger cell death. He also co-founded Theraptosis S.A. (Institut Pasteur spin off, 2001), a biopharmaceutical Company dedicated to exploit core apoptosis mechanisms for therapeutic purpose, where he served for 7.5 years as Chief Scientific Officer (CSO), including 5 years as Chief executive Officer (CEO). He coordinated and headed the preclinical development of a new caspase inhibitor (GMP manufacturing, efficacy, safety pharmacology, ADME, regulatory toxicology), and obtained from the European Medicine Agency (EMEA) the Orphan Drug Status for this drug to treat perinatal brain injury (ORPHA134079). EJ is co-inventor of 22 patent application families and co-author of 56 peer-reviewed publications with 4552 citations, with 8 cited > 150-fold, h-index=25 (average citation by item = 81.29). 18 invited conference, among 95 international and national communications. He has directly trained 14 students (4 post-doc, 5 Master 4 BSc. Students, 1 Medical Res.). He is editorial board member of Recent Patents on CNS Drug Discovery, external referee for NMRC and ANR, member of the scientific board of La Fondation Motrice (foundation for cerebral palsy), and was a nominated member at the National Committee of the CNRS (Section 25 physiology) from 2004 to 2008.
Biography Updated on 3 April 2011